This suggests that a more active immune response exists in the local tumor microenvironment of cancers with MSI+ and POLE hypermutant phenotypes, blocking PD-1/PD-L1; therefore, inducing an effective antitumor immune response, and that patients with MSI and POLE hypermutant phenotypes, may be a beneficial population for PD-1/PD-L1 inhibitors. The gene discussed is CD274; the disease is cancer.